Adenosine A3 Receptor

A subtype of ADENOSINE RECEPTOR that is found expressed in a variety of locations including the BRAIN and endocrine tissues. The receptor is generally considered to be coupled to the GI, INHIBITORY G-PROTEIN which causes down regulation of CYCLIC AMP.

Also Known As:

Networked: 95 relevant articles (5 outcomes, 11 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Jacobson, Kenneth A: 5 articles (03/2022 - 01/2015)
2.	Salvemini, Daniela: 3 articles (11/2020 - 01/2015)
3.	Feng, Xiao: 3 articles (01/2017 - 01/2014)
4.	He, Yanting: 3 articles (01/2017 - 01/2014)
5.	Wu, Weiyun: 3 articles (01/2017 - 01/2014)
6.	Ye, Shicai: 3 articles (01/2017 - 01/2014)
7.	Yu, Caiyuan: 3 articles (01/2017 - 01/2014)
8.	Zhou, Yu: 3 articles (01/2017 - 01/2014)
9.	Heitman, Laura H: 2 articles (03/2022 - 01/2019)
10.	Bai, Hui: 2 articles (01/2022 - 01/2022)

Related Diseases

1.	Infarction (Infarctions) 02/01/1997 - "The aim of this study was to determine whether selective activation of the adenosine A3 receptor reduces infarct size in a Langendorff model of myocardial ischemia-reperfusion injury. " 08/01/2001 - "Recent studies have demonstrated that the adenosine A1 receptor agonist 2-chloro-N6-cyclopentyladenosine (CCPA) and the adenosine A3 receptor agonist N6-(3-iodobenzyl)adenosine-5'-N-methyluronamide (IB-MECA) produce a delayed phase of protection against infarction similar to the late phase of ischemic preconditioning (PC). "
2.	Psoriasis (Pustulosis Palmaris et Plantaris) 01/01/2021 - "Optical control of adenosine A3 receptor function in psoriasis." 01/01/2022 - "Optical Control of Adenosine A3 Receptor Signaling: Towards a Multimodal Phototherapy in Psoriasis?" 01/01/2016 - "CF101, an adenosine A3 receptor agonist, is an orally bioavailable small molecule drug presenting an anti-psoriatic effect demonstrated in a Phase 2 clinical trial in psoriasis patients.<BR /> To evaluate the safety and efficacy of CF101 treatment in a Phase 2/3 study in patients with moderate to severe plaque-type psoriasis.<BR /> This multicenter, double-blind, 2-segment, placebo-controlled study randomized subjects with moderate to severe plaque psoriasis to CF101 1 or 2 mg, or placebo twice daily. "
3.	Ischemia 03/01/2005 - "Its protective effect against ischemia/reperfusion-related insults may involve activation of adenosine A3 receptors." 09/22/1994 - "Chronic treatment with the selective adenosine A3 receptor agonist N6-(3-iodobenzyl)adenosine-5'-N-methylcarboxamide (IB-MECA) administered prior to either 10 or 20 min forebrain ischemia in gerbils resulted in improved postischemic cerebral blood circulation, survival, and neuronal preservation. " 11/01/2014 - "Among endogenous molecules regulating vascular tone is adenosine, with the adenosine A3 receptor (A3AR) exerting cardioprotective properties in ischemia and reperfusion. " 06/09/1998 - "The adenosine A3 receptor-selective antagonist 3-ethyl 5-benzyl-2-methyl-6-phenyl-4-phenylethynyl-1, 4-(+/-)-dihydropyridine-3,5-dicarboxylate (MRS1191) caused a biphasic inhibition of the protective effect of the brief ischemia. " 01/01/2021 - "LJ529 was reported to attenuate inflammation through a Gi protein-coupled Adenosine A3 receptor (A3R) after ischemia. "
4.	Hypotension (Low Blood Pressure) 03/18/1996 - "The data provide further evidence of a key role for the mast cell in adenosine A3 receptor-mediated hypotension in this species." 07/01/1995 - "A role for mast cells in adenosine A3 receptor-mediated hypotension in the rat." 07/01/1995 - "1. The adenosine A3 receptor agonist, N6-2-(4-aminophenyl)ethyladenosine (APNEA) induces hypotension in the anaesthetized rat. " 05/01/1993 - "Adenosine A3 receptors mediate hypotension in the angiotensin II-supported circulation of the pithed rat." 07/01/1995 - "5. Plasma and serum histamine concentrations were markedly increased associated with the pronounced hypotensive responses induced by intravenous injections of APNEA (30 or 100 microg kg-1) in the presence of 8-SPT, or compound 48/80 (300 microg kg-1).6. Taken together the data implicate the mast cell in a key role in adenosine A3 receptor-mediated hypotension in the anaesthetized rat."
5.	Seizures (Absence Seizure) 02/24/1995 - "The effects of adenosine A3 receptor stimulation on seizures in mice." 04/29/1999 - "With the exception of the adenosine A3 receptor agonist, N6-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine (IB-MECA), all the agonists studied prevented the development of audiogenic seizures in a dose-dependent manner. " 02/24/1995 - "Since the combination of an arteriole-constricting compound 48/80 and hypotension-inducing clonidine injected prior to NMDA results in a significant protection against seizures, and since acute stimulation of adenosine A3 receptor causes both arteriolar constriction and severe hypotension, there is a possibility that the protection obtained by the acutely administered drug may result from inadequate delivery of chemoconvulsants to the brain. " 02/24/1995 - "Since several pathophysiological phenomena are common for both ischemia and seizures, we have explored the effect of acute and chronic administration of the adenosine A3 receptor selective agonist IB-MECA (N6-(3-iodobenzyl) adenosine-5'-N-methylcarboxamide) prior to seizures induced by N-methyl-D-aspartate (NMDA), pentamethylenetetrazole, or electric shock. "

Related Drugs and Biologics

1.	N(6)- (3- iodobenzyl)- 5'- N- methylcarboxamidoadenosine
2.	Adenosine A1 Receptor
3.	CF101
4.	Pancreatic Elastase (Elastase)
5.	p-Methoxy-N-methylphenethylamine
6.	PPAR gamma
7.	N-Methylaspartate (NMDA)
8.	Clonidine (ST 155)
9.	2- chloro- N(6)- (3- iodobenzyl)- 5'- N- methylcarbamoyl- 4'- thioadenosine
10.	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)

Related Therapies and Procedures

1.	Therapeutics
2.	Phototherapy (Light Therapy)
3.	Intravenous Injections